99-29. Draft Guidance for Industry on SUPAC-SS: Nonsterile Semisolid Dosage Forms, Manufacturing Equipment Addendum; Availability  

  • [Federal Register Volume 64, Number 2 (Tuesday, January 5, 1999)]
    [Notices]
    [Page 518]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-29]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    [Docket No. 95D-0349]
    
    
    Draft Guidance for Industry on SUPAC-SS: Nonsterile Semisolid 
    Dosage Forms, Manufacturing Equipment Addendum; Availability
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is announcing the 
    availability of a draft guidance for industry entitled ``SUPAC-SS: 
    Nonsterile Semisolid Dosage Forms, Manufacturing Equipment Addendum.'' 
    This draft guidance is intended to provide recommendations to 
    pharmaceutical manufacturers using the Center for Drug Evaluation and 
    Research's guidance for industry, ``SUPAC-SS Nonsterile Semisolid 
    Dosage Forms, Scale-Up and Post Approval Changes: Chemistry 
    Manufacturing and Controls; In Vitro Release Testing and In Vivo 
    Bioequivalence Documentation'' (SUPAC-SS).
    
    DATES: Written comments on the draft guidance document may be submitted 
    by March 8, 1999. General comments on agency guidance documents are 
    welcome at any time.
    
    ADDRESSES: Copies of this draft guidance are available on the Internet 
    at ``http://www.fda.gov/cder/guidance/index.htm.'' Written requests for 
    single copies of the draft guidance for industry should be submitted to 
    the Drug Information Branch (HFD-210), Center for Drug Evaluation and 
    Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, 
    MD 20857. Submit written comments on the draft guidance to the Dockets 
    Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers 
    Lane, rm. 1061, Rockville, MD 20852.
    
    FOR FURTHER INFORMATION CONTACT: Nancy B. Sager, Center for Drug 
    Evaluation and Research (HFD-357), Food and Drug Administration, 5600 
    Fishers Lane, Rockville, MD 20857, 301-594-5633.
    
    SUPPLEMENTARY INFORMATION: FDA is announcing the availability of a 
    draft guidance for industry entitled ``SUPAC-SS: Nonsterile Semisolid 
    Dosage Forms, Manufacturing Equipment Addendum.'' This document should 
    be used in conjunction with the guidance for industry, ``SUPAC-SS 
    Nonsterile Semisolid Dosage Forms, Scale-Up and Post Approval Changes: 
    Chemistry Manufacturing and Controls; In Vitro Release Testing and In 
    Vivo Bioequivalence Documentation'' (SUPAC-SS), which published in June 
    1997 (62 FR 32352, June 13, 1997), in determining what documentation 
    should be submitted to FDA regarding equipment changes made in 
    accordance with the recommendations of the SUPAC-SS guidance document.
         This draft level 1 guidance is being issued consistent with FDA's 
    good guidance practices (62 FR 8961, February 27, 1997). This draft 
    guidance represents the agency's current thinking on equipment changes 
    under SUPAC-SS. It does not create or confer any rights for or on any 
    person and does not operate to bind FDA or the public. An alternative 
    approach may be used if such approach satisfies the requirements of the 
    applicable statute, regulations, or both.
         Interested persons may submit written comments on the draft 
    guidance to the Dockets Management Branch (address above). Two copies 
    of any comments are to be submitted, except that individuals may submit 
    one copy. Comments are to be identified with the docket number found in 
    brackets in the heading of this document. The draft guidance and 
    received comments may be seen in the office above between 9 a.m. and 4 
    p.m., Monday through Friday.
    
        Dated: December 24, 1998.
    William K. Hubbard,
    Associate Commissioner for Policy Coordination.
    [FR Doc. 99-29 Filed 1-4-99; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
01/05/1999
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
99-29
Dates:
Written comments on the draft guidance document may be submitted by March 8, 1999. General comments on agency guidance documents are welcome at any time.
Pages:
518-518 (1 pages)
Docket Numbers:
Docket No. 95D-0349
PDF File:
99-29.pdf